Adam Sperling, MD, PhD
@adamssperling.bsky.social
📤 517
📥 151
📝 28
Physician scientist UCLA --> BWH <--> DFCI —> Stanford. Myeloma, CAR-T, CHIP, MDS.
reposted by
Adam Sperling, MD, PhD
Ann Mullally
8 days ago
After a fantastic MGR today, we are thrilled to welcome Dr. Ross Levine back for our
#hematology
seminar tomorrow - very thankful to Ross for such & engaging & fun visit!
#MPNsm
@stanforddeptmed.bsky.social
@rosslevinemd.bsky.social
@mskcancercenter.bsky.social
add a skeleton here at some point
0
6
2
reposted by
Adam Sperling, MD, PhD
Dana-Farber Cancer Institute
about 1 month ago
Congratulations to Irene Ghobrial, MD, recipient of Senior Researcher Prize of the Francesca Cassinelli Award for 2025. The award recognizes Ghobrial's exceptional scientific excellence, international leadership, and impactful contributions to multiple myeloma. Learn more:
bit.ly/4cFHFV4
0
1
1
Incredible
add a skeleton here at some point
about 1 month ago
1
2
1
Ohh, awesome! I was actually wondering about this exact thing recently. It's super helpful to have data to answer the question.
add a skeleton here at some point
about 1 month ago
0
2
1
Congrats
@paralkarlab.bsky.social
!
add a skeleton here at some point
about 1 month ago
1
0
0
reposted by
Adam Sperling, MD, PhD
Dana-Farber Cancer Institute
2 months ago
We are profoundly grateful to announce the largest single gift in our 78-year history through a new joint commitment from Josh and Anita Bekenstein and the Jonathan Lavine and Jeannie Lavine family.
1
5
3
reposted by
Adam Sperling, MD, PhD
Nikhil Munshi, MD
4 months ago
Very important new paper by Samur et al on SMM in JCO - will change our thinking!
@pedalheadphx.bsky.social
@myeloma-society.bsky.social
@themmrf.bsky.social
@imfmyeloma.bsky.social
@szusmani.bsky.social
#
ascopubs.org/doi/10.1200/...
loading . . .
Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma
PURPOSEThe diagnosis of smoldering multiple myeloma (SMM) primarily relies on clinical features such as plasma cell involvement, immunoglobulin protein levels, and end-organ damage. However, as early ...
https://ascopubs.org/doi/10.1200/JCO-25-00289
0
2
1
Can't wait.
add a skeleton here at some point
5 months ago
0
1
0
reposted by
Adam Sperling, MD, PhD
ernstlaboratory.bsky.social
5 months ago
@paralkarlab.bsky.social
Hello, since you are a hematology/oncology influencer, could you re-post my thing about the Myeloid Workshop being on despite ASH not getting it up on the website? Thank you!
1
2
2
Congrats to Yu-Hsiang Chen, Pavan Bachireddy, and team at
@mdanderson.bsky.social
for getting this important work out. By understanding how MRD cells escape therapy at a more basic level hopefully we can eventually cure more patients with MDS.
www.biorxiv.org/content/10.1...
loading . . .
Molecular and cellular dynamics of measurable residual disease progression in myelodysplastic syndromes
Cancer relapse after treatment invariably proceeds from the persistence and progression of measurable residual disease (MRD), an ultrasmall malignant population. Despite the poor prognostic impact est...
https://www.biorxiv.org/content/10.1101/2025.10.17.682671v1
6 months ago
0
3
0
reposted by
Adam Sperling, MD, PhD
Virginia Gewin
6 months ago
Journalist here I’m interested in talking to a federal agency scientist who was fired, then rehired. I can keep you anonymous. I’m on Signal ginnyg.04 Reposts are appreciated!
4
311
314
reposted by
Adam Sperling, MD, PhD
Dana-Farber Cancer Institute
7 months ago
Congratulations to Anthony Letai, MD, PhD, on being named the new director of the National Cancer Institute. His appointment is a testament to our continuing commitment to innovation and collaboration. Learn more:
bit.ly/4pRWiZy
0
13
4
reposted by
Adam Sperling, MD, PhD
Til Steinicke
7 months ago
Epigenetic diagnosis of acute leukemia within two hours from sample receipt 🚀 Very happy to share the results of a great collaboration between
@hovestadt.bsky.social
and Griffin Labs, I co-led with
@sbenfatto.bsky.social
, published today in
@natgenet.nature.com
📄
www.nature.com/articles/s41...
🧵1/n
loading . . .
Rapid epigenomic classification of acute leukemia - Nature Genetics
The authors present a molecular classification of acute leukemia using 5-methylcytosine signatures, together with a neural network-based classifier for clinical use.
https://www.nature.com/articles/s41588-025-02321-z
2
36
17
Dr. Rashidian from
@danafarbernews.bsky.social
presenting his work at the 2025
@myeloma-society.bsky.social
meeting.
7 months ago
1
6
0
reposted by
Adam Sperling, MD, PhD
Dana-Farber Cancer Institute
8 months ago
Please join us in congratulating Alice Shaw, MD, PhD, on being named our next Chair of the Department of Medical Oncology. Learn more:
bit.ly/45wiiQ6
loading . . .
Alice T. Shaw named Chair of Department of Medical Oncology at Dana-Farber Cancer Institute | Dana-Farber Cancer Institute
Alice T. Shaw, MD, PhD, was named Chair of the Department of Medical Oncology at Dana-Farber Cancer Institute, in an announcement today.
https://bit.ly/45wiiQ6
0
10
7
reposted by
Adam Sperling, MD, PhD
Elizabeth McKenna
9 months ago
It's my first
#newPI
roll call on BlueSky! Calling all new
#cancer
PIs who just started or who are about to start their labs! Please say hi and what you work on so I can follow you if I don't already! 😃
0
27
13
reposted by
Adam Sperling, MD, PhD
ernstlaboratory.bsky.social
9 months ago
The Myeloid Workshop is back in ASH! Please contact the organizers if you have an exciting story that will not be out by December they are: Zuzana Tothova ,
@ernstlaboratory.bsky.social
@steidluli.bsky.social
@ericpietras.bsky.social
@kathrinbernt.bsky.social
@gritsmanlab.bsky.social
0
19
8
Super interesting. Congrats on getting this out.
add a skeleton here at some point
10 months ago
1
3
1
reposted by
Adam Sperling, MD, PhD
Katherine King MD PhD
10 months ago
And here it is! Our study in clonal hematopoiesis and Alzheimer’s disease — product of 5 years’ gestation.
urldefense.proofpoint.com/v2/url?u=htt...
loading . . .
ScienceDirect.com | Science, health and medical journals, full text articles and books.
https://urldefense.proofpoint.com/v2/url?u=https-3A__kwnsfk27.r.eu-2Dwest-2D1.awstrack.me_L0_https-3A-252F-252Fauthors.elsevier.com-252Fsd-252Farticle-252FS1934-2D5909-2825-2900228-2D0_1_01020197cba305d3-2D5bbecc77-2D8127-2D444d-2D9880-2D431fbf5f4c58-2D000000_87dCfUn5U-2Doje2HGDdaqFv-5FhXyM-3D433&d=DwMFaQ&c=ZQs-KZ8oxEw0p81sqgiaRA&r=nJ9DzFsrKFfaiebZnvX5vg&m=sdeeYm1xGmAjcrMAV7thltzj317v3ACeqHKcjU44B_YfLNwOWzxX12uxMaBBcAHA&s=Ed3vsxv-PDgOPCdJGgIn4bOsoZGqeU1MTiMDEPUtQfs&e=
4
23
9
reposted by
Adam Sperling, MD, PhD
Nikhil Munshi, MD
10 months ago
Major Regulatory Milestone in MM: In response to an application by I2TEAMM and IMFmyeloma, the European Medicines Agency has officially endorsed MRD as an early endpoint in clinical trials for Myeloma. This marks a transformative step forward in drug development !!
@vincentrk.bsky.social
1
5
2
reposted by
Adam Sperling, MD, PhD
Myeloma Society
10 months ago
We are proud to announce that the International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma has been published by the Journal of Clinical Oncology!
ascopubs.org/doi/10.1200/...
0
4
3
reposted by
Adam Sperling, MD, PhD
Scott Delaney
about 1 year ago
As someone directly affected by this, let me be clear: I'd rather lose my job because Harvard chose to fight than keep my job and see a generation of white supremacists parade its corpse around like a war trophy.
add a skeleton here at some point
37
1954
412
reposted by
Adam Sperling, MD, PhD
Dana-Farber Cancer Institute
about 1 year ago
Meet Yuxin Liu, MD, who treats patients with multiple myeloma and other plasma cell disorders. Her clinical research focuses on novel therapies in newly diagnosed and relapsed multiple myeloma.
https://bit.ly/3FljInk
0
8
1
reposted by
Adam Sperling, MD, PhD
The ASCO Post
about 1 year ago
Diet plays a pivotal role in cancer care, yet clear guidelines remain scarce. Dr. Urvi A. Shah explores the evidence, challenges, and need for more robust dietary intervention trials in oncology.
ascopost.com/news/march-2...
#OncologyResearch
#CancerCare
0
1
1
Multiple myeloma is a terrible disease.
add a skeleton here at some point
about 1 year ago
0
3
0
reposted by
Adam Sperling, MD, PhD
Julia Maxson
about 1 year ago
Kudos to our professional societies for advocating for continued funding for lifesaving research through the NIH. There is a link at the end of the statement to contact your representatives!! 👇
add a skeleton here at some point
0
2
1
reposted by
Adam Sperling, MD, PhD
Julia Maxson
about 1 year ago
I feel like we could all use something fun to look forward to right about now!!! 🧪🧪🧪 Abstract submission and registration are open for the FASEB Hematologic Malignancies Conference. This is always the BEST meeting!!! Please RT!
events.faseb.org/event/hemato...
0
8
8
reposted by
Adam Sperling, MD, PhD
PLMcCarthyBuffalo
about 1 year ago
ashpublications.org/blood/articl...
loading . . .
Evaluating the impact of CRBN mutations on response to immunomodulatory drugs and novel CRBN-binding agents in myeloma
Key Points. CRBN missense mutations identified in patients were modelled to explore their effect on CRBN function with IMiD and CELMoD therapy.Mutations le
https://ashpublications.org/blood/article/doi/10.1182/blood.2024025861/535234/Evaluating-the-impact-of-CRBN-mutations-on
0
2
1
reposted by
Adam Sperling, MD, PhD
Ann Mullally
over 1 year ago
Delighted to share our
#hematology
review article on mutant calreticulin in
#MPN
Congrats to co-authors Drs. Mifra Faiz, Merle Riedemann & Jonas Jutzi. We hope it’s a useful resource, link below!
@stanforddeptmed.bsky.social
link.springer.com/article/10.1...
loading . . .
Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications - Current Hematologic Malignancy Reports
Purpose of Review More than a decade following the discovery of Calreticulin (CALR) mutations as drivers of myeloproliferative neoplasms (MPN), advances in the understanding of CALR-mutant MPN continu...
https://link.springer.com/article/10.1007/s11899-024-00749-4
0
25
7
reposted by
Adam Sperling, MD, PhD
Dana-Farber Cancer Institute
over 1 year ago
Three leaders from our cellular therapy & stem cell transplant program were at the White House this week to discuss cell and gene therapy development. We’re grateful to Drs. Corey Cutler, Eric Smith, and Jose Cancelas for their ongoing work to improve access & outcomes with these therapies.
0
12
1
reposted by
Adam Sperling, MD, PhD
Peter van Galen
over 1 year ago
Our latest work is now available to read on bioRxiv! Very proud of this and its potential implications for patients with acute myeloid leukemia 🩸 🧪 🔬💊 **eIF4A-mediated translation initiation as an AML cell vulnerability that can be co-targeted with BCL-2 inhibition**
www.biorxiv.org/content/10.1...
3
42
16
reposted by
Adam Sperling, MD, PhD
Fred Hutch
over 1 year ago
Please join us in welcoming Madhav Dhodapkar, MBBS, as the new leader of Fred Hutch’s
#Myeloma
Program. Dr. Dhodapkar, a board-certified hematologist and oncologist, is a renowned expert in the treatment of multiple myeloma and other hematologic malignancies.
#ASH24
1/3
1
25
8
Interesting. Raises the question of how important the disrupted immune microenvironment is for supporting myeloma growth as opposed to being a consequence of the myeloma and therapy.
add a skeleton here at some point
over 1 year ago
0
12
0
reposted by
Adam Sperling, MD, PhD
American Society of Hematology
over 1 year ago
The highly anticipated late-breaking abstracts have been posted:
bit.ly/2024_ash_lbas
#ASHKudos
to the presenters! Discover high-impact
#hematology
research at
#ASH24
! It’s not too late to register to join us in San Diego or virtually.
#BloodSky
#HemeSky
0
25
3
reposted by
Adam Sperling, MD, PhD
Nikhil Munshi, MD
over 1 year ago
An interesting paper in Blood by Dr. Samur suggesting that the cell that eventually becomes myeloma first acquires extra chromosome in 2nd decade of life and becomes fully hyperdiploid by 3rd. Implication for many cancers.
@pedalheadphx.bsky.social
@auclairdan.bsky.social
@szusmani.bsky.social
3
23
10
reposted by
Adam Sperling, MD, PhD
Jonathan Keats, PhD 🇨🇦
over 1 year ago
Oh right, IMS might drive more myeloma peeps to this platform beyond a few others like
@adamssperling.bsky.social
, for finding myeloma content add the MyelomaSky feed, should pick up anything with myeloma,
#myeloma
,
#mmsm
,
#smm
,
#mgus
, and a few other tags
1
3
2
reposted by
Adam Sperling, MD, PhD
Karolin Luger
about 2 years ago
The chromatin field lost one of the Greats - Michael Grunstein (UCLA) passed away today. There was a time when histones were deemed unimportant. Michael's work brought them to center stage. His contributions to the field are legion. he will be missed
3
30
11
you reached the end!!
feeds!
log in